CA3243492A1 — Liquid pharmaceutical formulation of omeprazole or esomeprazole
Assigned to Alkaloid AD Skopje · Expires 2023-09-21 · 3y expired
What this patent protects
"The present invention relates to a novel two-component formulation of an active ingredient, in particular a proton pump inhibitor. The two-component formulation is stable during prolonged periods of storage, and the components are combined to give a formulation that is suita…
USPTO Abstract
"The present invention relates to a novel two-component formulation of an active ingredient, in particular a proton pump inhibitor. The two-component formulation is stable during prolonged periods of storage, and the components are combined to give a formulation that is suitable for oral administration, having good palatability and good efficacy."
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.